ArticleCancer cell international2012
The role of A20 in the pathogenesis of lymphocytic malignancy.
Article in Cancer cell international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- TNFAIP3 mutation is an independent poor overall survival factor for patients with T-cell acute lymphoblastic leukemia.Cancer medicine · 2023Article
- TNFAIP3 mutation may be associated with favorable overall survival for patients with T-cell lymphoma.Cancer cell international · 2021Article
- Autophagy in Human T-Cell Leukemia Virus Type 1 (HTLV-1) Induced Leukemia.Frontiers in oncology · 2021Review
- Degradation of p47 by autophagy contributes to CADM1 overexpression in ATLL cells through the activation of NF-κB.Scientific reports · 2019Article
- CYLD, A20 and OTULIN deubiquitinases in NF-κB signaling and cell death: so similar, yet so different.Cell death and differentiation · 2017Review
- Overexpression of MALT1-A20-NF-κB in adult B-cell acute lymphoblastic leukemia.Cancer cell international · 2015Article
- Characteristics of CARMA1-BCL10-MALT1-A20-NF-κB expression in T cell-acute lymphocytic leukemia.European journal of medical research · 2014Article
- Alternative expression pattern of MALT1-A20-NF-κB in patients with rheumatoid arthritis.Journal of immunology research · 2014Article
- Abnormal expression of A20 and its regulated genes in peripheral blood from patients with lymphomas.Cancer cell international · 2014Article
- The TCR γδ repertoire and relative gene expression characteristics of T-ALL cases with biclonal malignant Vδ1 and Vδ2 T cells.DNA and cell biology · 2014Article
- Changes in the MALT1-A20-NF-κB expression pattern may be related to T cell dysfunction in AML.Cancer cell international · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune phenomena were identified in many different cases of hematological diseases and solid tumors, which may be due to alterations in the expression and function of the NF-κB signaling pathway. Recently, a number of studies have shown that the deletion or mutation of A20, a negative regulator of NF-κB, is frequently found in lymphomas, suggesting that it may be a linker between the altered immune response and leukemogenesis. The aim of this review is to summarize current findings of the A20 biological functions and its molecular mechanism as a tumor suppressor and immune regulator. The identification of A20 mutations and deletions in lymphocytic malignancy and the predictive significance of these aberrations are also reviewed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.